(Kuala Lumpur, 9th) The President of the Chinese President Tan Sri Wu Tianquan said that the coronavirus vaccine developed by China is currently in the third phase of clinical trials under the UN World Health Organization. Once it has passed the market and obtained my country’s halal certification After that, it can be emergency in our country.
He said that President Hua fully supports the government's emergency response to the introduction of Chinese vaccines. In this regard, we are also prepared to cooperate with the governments of Malaysia and China and relevant parties, in accordance with all necessary regulations and regulations, to assist relevant enterprises in docking to introduce vaccines to Malaysia.
Wu Tianquan is also the president of the Chinese Assembly Hall in Sabah. He recently communicated with the leadership of the agency’s chief executive, Dr. Akma Yusuf, at the headquarters of the Malaysian Clinical Research Institute (CRM) to understand the organization’s operating procedures. In a statement issued today, it said.
According to the agency, relevant preparations have been made to introduce Chinese vaccines.
Wu Tianquan said that President Hua is also actively contacting relevant Chinese parties, hoping to assist and coordinate the introduction of approved vaccines to Malaysia, and cooperate with all departments and institutions, including Malaysian clinical research institutions, to help my country connect with enterprises. Anti-epidemic work, especially in civilian epidemic prevention.
He described that the Malaysian Clinical Research Institute was established in 2012 on the recommendation of the Malaysian Clinical Research Center (CRC), mainly to assist the government in managing overseas clinical research and to promote important work such as clinical research in my country. It is also well regulated by the National Pharmaceutical Regulatory Agency (NPRA) and the Medical Research and Ethics Committee (MREC).
At the same time, Wu Tianquan, who is also the major shareholder and executive chairman of Elite Holdings Limited (GLOTEC, 5220, main board industrial stock), a company listed on the Kuala Lumpur Stock Exchange, said that the group's subsidiaries are also discussing participation in the project of introducing Chinese vaccines, hoping to help Give corporate feedback on the national anti-epidemic work.
He said that in particular, the country is currently facing the third wave of attacks, and many regions in the country are trapped in yellow and red zones. After the implementation of the state closure and cross-county ban, the government, enterprises and businesses, including the people, must work together. Cooperate, comprehensively prevent and fight the epidemic, so as to flatten the curve as soon as possible.
"This includes arrangements for the introduction of vaccines. We hope that vaccines can be approved for market as soon as possible to resolve the crisis."
He pointed out that the Chinese government, through the Ministry of Science, Technology and Innovation, is also responsible for consulting with relevant Chinese government departments and institutions, and deciding on cooperation and procurement plans for COVID-19 vaccines. According to Carey, Minister of Science and Arts, the third phase clinical trial data of COVID-19 vaccine is expected to be analyzed by the end of this year. The department, the Ministry of Health and the General Prosecutor's Office are discussing relevant legal affairs and procurement models.
The exceptional profit for the reporting quarter was due to a Gain on disposal of gold royalty of 22m ( refer to cashflow statements) . The reporting revenue & gross profit were down .
alahai elok2 dah stabilizes 43-44c, now gone down unsupported. Seems to be intentionally blocked for further going-up. What games is this? I can't really understand!... volume remains low for the force selling cause. Who is actually liquidating? The good quarterly result makes no diff. Seems to go back where it started at 38c!
Technically, it is not looking good for GLOTEC as its 20-Day Moving Average is sloping downward and its price action is below the Moving Average line. The recent downward movement in price has brought us to the technically important level of 0.395. Failure to find support at this level may accentuate the bearish move. The RSI indicator is giving a reading in the oversold region. This may indicate the price decline may be over-extended. The price and volume action at the 0.395 support level is to be monitored carefully.
On behalf of the Board of Directors of GFB, we are pleased to announce that NuEnergy Gas Limited (“NuEnergy”), a subsidiary of GFB which is listed on the Australian Securities Exchange (“ASX”) has today announced on ASX that NuEnergy has received an Acknowledgement letter (“AL”) from the Indonesia’s Special Task Force for Upstream Oil and Gas Business Activities (“SKK Migas”) that:
confirms the discoveries of natural gas in the Muara Enim Production Sharing Contract (“PSC”) area; acknowledges the completion of exploration firm commitments by NuEnergy in respect of the Muara Enim PSC; and allows NuEnergy to submit a plan of development within the next 3 years from 18 January 2021.
Further details are enclosed in the attached announcement made by NuEnergy.
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
asd88
809 posts
Posted by asd88 > 2020-10-20 13:32 | Report Abuse
Been in collection mode for awhile now